MedinCell S.A. (EPA:MEDCL)
25.78
-0.16 (-0.62%)
Aug 3, 2026, 2:04 PM CET
MedinCell Balance Sheet
Financials in millions EUR. Fiscal year is April - March.
Millions EUR. Fiscal year is Apr - Mar.
Assets
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Cash & Equivalents | 62.79 | 59.04 | 19.46 | 6.47 | 24.62 |
Short-Term Investments | 22.03 | 12.86 | - | 0 | 2.57 |
Cash & Short-Term Investments | 84.82 | 71.9 | 19.46 | 6.47 | 27.18 |
Cash Growth | 17.98% | 269.46% | 200.77% | -76.20% | -46.28% |
Accounts Receivable | 4.5 | 3.15 | 2.25 | 2.09 | 0.8 |
Other Current Assets | 7.42 | 5.57 | 5.54 | 11.01 | 6.09 |
Total Current Assets | 96.74 | 80.62 | 27.26 | 19.57 | 34.07 |
Net Property, Plant & Equipment | 5 | 5.27 | 5.43 | 6.37 | 7.03 |
Other Intangible Assets | 3.48 | 2.65 | 2.45 | 1.93 | 1.67 |
Long-Term Investments | 0.02 | 0.02 | 0.02 | 0.02 | 0.01 |
Other Long-Term Assets | 2.83 | 1.9 | 1.79 | 1.46 | 1.52 |
Total Assets | 108.06 | 90.45 | 36.95 | 29.34 | 44.3 |
Liabilities
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Accounts Payable | 3.39 | 4 | 1.85 | 4.18 | 2.98 |
Current Portion of Long-Term Debt | 2.64 | 6.62 | 5.52 | 39.76 | 27.76 |
Current Portion of Leases | 0.67 | 0.67 | 0.64 | 0.64 | 0.58 |
Other Current Liabilities | 14.02 | 18.58 | 8.46 | 12.45 | 6.91 |
Total Current Liabilities | 20.71 | 29.87 | 16.47 | 57.03 | 38.24 |
Long-Term Debt | 52.39 | 49.42 | 50.54 | 11.71 | 16.25 |
Long-Term Leases | 1.72 | 2.05 | 2.26 | 2.54 | 2.9 |
Other Long-Term Liabilities | 30.17 | 25.48 | 8.5 | 0.35 | 0.29 |
Total Long-Term Liabilities | 84.28 | 76.95 | 61.3 | 14.61 | 19.43 |
Total Liabilities | 104.99 | 106.82 | 77.77 | 71.63 | 44.3 |
Shareholders' Equity
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Common Stock | 0.36 | 0.33 | 0.29 | 0.25 | 0.25 |
Additional Paid-in Capital | 45.44 | 70.73 | 31.01 | 7.42 | 6.91 |
Retained Earnings | -42.73 | -87.42 | -72.13 | -49.96 | -20.54 |
Total Common Shareholders' Equity | 3.06 | -16.37 | -40.82 | -42.29 | -13.37 |
Shareholders' Equity | 3.06 | -16.37 | -40.82 | -42.29 | -13.37 |
Total Liabilities & Equity | 108.06 | 90.45 | 36.95 | 29.34 | 30.93 |
Additional Metrics
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Total Debt | 57.41 | 58.76 | 58.96 | 54.65 | 47.49 |
Net Cash (Debt) | 27.41 | 13.14 | -39.5 | -48.18 | -20.31 |
Net Cash Growth | 108.61% | - | - | - | - |
Net Cash Per Share | 0.82 | 0.44 | -1.39 | -1.91 | -0.82 |
Book Value | 3.06 | -16.37 | -40.82 | -42.29 | -13.37 |
Book Value Per Share | 0.09 | -0.55 | -1.44 | -1.68 | -0.54 |
Tangible Book Value | -0.42 | -19.01 | -43.27 | -44.22 | -15.04 |
Tangible Book Value Per Share | -0.01 | -0.64 | -1.52 | -1.76 | -0.60 |